IRONWOOD PHARMACEUTICALS INC - DBCV 2.250% 6/1 Institutional Ownership

CUSIP: 46333XAD0

13F Institutional Holders and Ownership History from Q2 2016 to Q2 2022

Type / Class
Debt / DBCV 2.250% 6/1
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Investment Quick Answers

What is CUSIP 46333XAD0?
CUSIP 46333XAD0 identifies 46333XAD0 - IRONWOOD PHARMACEUTICALS INC - DBCV 2.250% 6/1 in SEC 13F datasets.

Where can I see the latest institutional holders?
Use the ownership history tables below to review the newest available institutional filing periods.

Institutional Holders of IRONWOOD PHARMACEUTICALS INC - DBCV 2.250% 6/1 across Reporting Periods

Period Principal Value Change Price (% of par) (Median) Investors
2022 Q2 $0 $0 -$111,251,427 0
2022 Q1 $109,604,000 $111,251,427 +$2,037,726 101.74% 21
2021 Q4 $107,604,000 $112,180,532 -$1,840,097 103.98% 18
2021 Q3 $114,312,000 $134,119,152 +$2,268,648 109.05% 20
2021 Q2 $112,262,000 $122,725,873 -$6,590,626 109.18% 19
2021 Q1 $119,311,500 $128,855,129 -$6,578,844 107.74% 22
2020 Q4 $125,397,000 $135,816,410 +$4,430,916 108.2% 20
2020 Q3 $124,046,000 $128,027,390 -$69,665 103.41% 20
2020 Q2 $121,484,000 $127,575,224 +$10,554,009 104.95% 22
2020 Q1 $110,517,000 $116,165,833 -$10,001,501 105.27% 21
2019 Q4 $116,080,000 $135,747,646 +$15,534,039 116.95% 21
2019 Q3 $102,938,901 $103,141,953 -$172,928,867 100.15% 21
2019 Q2 $264,710,153 $286,598,293 -$31,001,949 106.95% 32
2019 Q1 $292,319,200 $325,972,061 -$26,868,282 110.31% 30
2018 Q4 $319,412,000 $303,342,038 -$28,988,626 93.99% 30
2018 Q3 $309,737,002 $402,581,410 -$1,594,319 129.85% 32
2018 Q2 $310,819,002 $415,523,563 -$26,983,547 133.12% 33
2018 Q1 $333,479,002 $393,694,562 -$3,090,166 118.01% 34
2017 Q4 $336,804,000 $391,965,869 -$958,072 116.25% 33
2017 Q3 $337,289,000 $401,585,826 -$5,078,431 119.02% 31
2017 Q2 $338,036,000 $454,348,199 +$1,624,126 133.99% 32
2017 Q1 $337,245,000 $421,082,000 +$749,313 124.74% 30
2016 Q4 $341,855,000 $393,563,000 -$9,046,539 114.92% 39
2016 Q3 $349,595,000 $417,856,000 +$61,763,506 119.5% 37
2016 Q2 $298,285,000 $308,662,000 +$308,662,000 103.49% 31